bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Other EventsItem 8.01 Other Events
On December 10, 2017, bluebird bio, Inc. (“bluebird”) issued a press release announcing data presented at the 58th Annual Meeting of the American Society ofHematology (“ASH”) from the CRB-401 clinical study of the bb2121 product candidate in patients with relapsed/refractory multiple myeloma.
Also on December 10, 2017, bluebird issued a press releas announcing data presented at ASH from the Northstar (HGB-204) and Northstar-2 (HGB-207) clinical studies of the LentiGlobin product candidate in patients with transfusion-dependent beta-thalassemia, and a press release announcing data presented at ASH from the HGB-206 clinical study of the LentiGlobin product candidate in patients with severe sickle cell disease.
On December 11, 2017, bluebird issued a press release announcing data presented at ASH from the HGB-205 clinical study of the LentiGlobin product candidate in patients with severe sickle cell disease and transfusion-dependent beta-thalassemia.
The full text of bluebird’s press releases regarding these announcements are filed as Exhibits 99.1, 99.2, 99.3, and 99.4 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
bluebird bio, Inc. ExhibitEX-99.1 2 blue-ex991_9.htm EX-99.1 blue-ex991_9.htm Exhibit 99.1 Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting Overall response rate (ORR) of 94% in patients in active dose cohorts (doses above 50 x 106 CAR + T-cells) Complete Response (CR) rate of 56% observed in patients in active dose cohorts Median progression free survival (PFS) not reached with median follow up of 40 weeks in active dose cohorts Nine of 10 (90%) of patients evaluable for minimal residual disease (MRD) status were found to be MRD-negative Summit,…To view the full exhibit click here
About bluebird bio, Inc. (NASDAQ:BLUE)
bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
